Orthocell Limited

ASX:OCC ISIN:AU000000OCC6

Orthocell Limited ASX:OCCOrthocell Limited (ASX:OCC) is a commercial-stage, regenerative medicine company focused on developing products for a variety of tendon, cartilage and soft tissue injuries. Orthocell's portfolio of products include TGA-approved stem cell therapies Autologous Tenocyte Implantation (Ortho-ATI*TM) and Autologous Chondrocyte Implantation (Ortho-ACI*TM), which aim to regenerate damaged tendon and cartilage tissue. The Company's other major product is Celgro*TM, a collagen medical device which facilitates tissue repair and healing in a variety of orthopaedic, reconstructive and surgical applications and is being readied for first regulatory approvals.

 
 
 

查看其它语言版本

新闻

Orthocell(ASX:OCC)公司软组织修复技术获中国专利

🕔1/16/2015 4:00:27 PM 6084

ACB News《澳华财经在线》报道,Orthocell 15日公告,其用于修复软组织的生物材料获得中国技术专利,专利号为 CN102159256 B,专利描述:"用于细胞生长和重建的胶原支架技术"。该技术主要用于制造修复软组织损伤的生物支架,在修复软组织损伤,如肌腱,软骨和耳膜损伤以及干细胞向手术创面传递有很好的辅助作用。

阅读全文
###

8,872 公司背景浏览

  • 本页浏览人次: (过去7日: 15) (过去30日: 57) (自发布以来: 4028) 

公司详细信息

更多新闻纪录

  • 2024/03/25: Part 1 Remplir US Market Authorisation Successfully Complete*
  • 2024/03/11: Cleansing Notice*
  • 2024/03/11: Application for quotation of securities - OCC*
  • 2024/03/11: Application for quotation of securities - OCC*
  • 2024/02/28: Cleansing Notice*
  • 2024/02/23: Appendix 4D & Half-Year Financial Statements*
  • 2024/02/22: Proposed issue of securities - OCC*
  • 2024/02/22: Strategic Placement to Raise $3.5 million*
  • 2024/02/20: Trading Halt*
*refer to company website